BACKGROUND: We previously correlated non-Hodgkin's lymphoma (NHL) histology with (18)fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) intensity: a standardized uptake value (SUV)>10 predicted aggressive lymphoma with >80% certainty and an SUV >13, with >90% certainty. PATIENTS AND METHODS: To evaluate SUV in transformed lymphoma, we identified all FDG-PET scans for NHL at Memorial Sloan-Kettering Cancer 1999-2007 with (i) biopsy-proven transformation, (ii) no therapy 60 days before PET scan and (iii) FDG-PET scans no more than 60 days before or 90 days after transformation. RESULTS: In 5 of 40 patients, the biopsy site was excised before PET; in two, only marrow was biopsied. In the remaining 33 patients, the SUV of the biopsy site ranged from 3 to 38, mean 14, median 12. Eighteen of 33 biopsies (55%) had an SUV>10 and 16 (48%)>13. The highest SUV in a transformed lymphoma PET scan (SUV(study-max)) ranged from 3.2 to 40, mean 15, median 12. Twenty-five of 40 patients (63%) presented with an SUV(study-max)>10 and 20 (50%)>13. CONCLUSIONS: Like de novo aggressive lymphomas, the majority of transformations have a high SUV(study-max) for a given pretreatment staging study, although many do not have very high values. Transformation should be suspected in indolent lymphoma with high SUVs on FDG-PET. Biopsies should be directed to the site of greatest FDG avidity.
BACKGROUND: We previously correlated non-Hodgkin's lymphoma (NHL) histology with (18)fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) intensity: a standardized uptake value (SUV)>10 predicted aggressive lymphoma with >80% certainty and an SUV >13, with >90% certainty. PATIENTS AND METHODS: To evaluate SUV in transformed lymphoma, we identified all FDG-PET scans for NHL at Memorial Sloan-Kettering Cancer 1999-2007 with (i) biopsy-proven transformation, (ii) no therapy 60 days before PET scan and (iii) FDG-PET scans no more than 60 days before or 90 days after transformation. RESULTS: In 5 of 40 patients, the biopsy site was excised before PET; in two, only marrow was biopsied. In the remaining 33 patients, the SUV of the biopsy site ranged from 3 to 38, mean 14, median 12. Eighteen of 33 biopsies (55%) had an SUV>10 and 16 (48%)>13. The highest SUV in a transformed lymphoma PET scan (SUV(study-max)) ranged from 3.2 to 40, mean 15, median 12. Twenty-five of 40 patients (63%) presented with an SUV(study-max)>10 and 20 (50%)>13. CONCLUSIONS: Like de novo aggressive lymphomas, the majority of transformations have a high SUV(study-max) for a given pretreatment staging study, although many do not have very high values. Transformation should be suspected in indolent lymphoma with high SUVs on FDG-PET. Biopsies should be directed to the site of greatest FDG avidity.
Authors: E Giné; S Montoto; F Bosch; L Arenillas; S Mercadal; N Villamor; A Martínez; L Colomo; E Campo; E Montserrat; A López-Guillermo Journal: Ann Oncol Date: 2006-08-28 Impact factor: 32.976
Authors: N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield Journal: J Clin Oncol Date: 1999-12 Impact factor: 44.544
Authors: I Buchmann; M Reinhardt; K Elsner; D Bunjes; C Altehoefer; J Finke; E Moser; G Glatting; J Kotzerke; C A Guhlmann; H Schirrmeister; S N Reske Journal: Cancer Date: 2001-03-01 Impact factor: 6.860
Authors: Heiko Schöder; Yusuf E Erdi; Kenneth Chao; Mithat Gonen; Steven M Larson; Henry W D Yeung Journal: J Nucl Med Date: 2004-04 Impact factor: 10.057
Authors: K Spaepen; S Stroobants; P Dupont; P Vandenberghe; J Thomas; T de Groot; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef Journal: Ann Oncol Date: 2002-09 Impact factor: 32.976
Authors: Jacobus F A Jansen; Heiko Schöder; Nancy Y Lee; Hilda E Stambuk; Ya Wang; Matthew G Fury; Snehal G Patel; David G Pfister; Jatin P Shah; Jason A Koutcher; Amita Shukla-Dave Journal: Int J Radiat Oncol Biol Phys Date: 2011-01-13 Impact factor: 7.038
Authors: Bouthaina S Dabaja; Jack Phan; Osama Mawlawi; L Jeffrey Medeiros; Carol Etzel; Fu-Wen Liang; Donald Podoloff; Yasuhiro Oki; Fredrick B Hagemeister; Hubert Chuang; Luis E Fayad; Jason Robert Westin; Ferial Shihadeh; Pamela K Allen; Christine F Wogan; Maria A Rodriguez Journal: Leuk Lymphoma Date: 2013-05-07